164 related articles for article (PubMed ID: 38916481)
1. Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies.
Dell'isola GB; Verrotti A; Sciaccaluga M; Roberti R; Parnetti L; Russo E; Costa C
Expert Opin Pharmacother; 2024 Jun; ():1-10. PubMed ID: 38916481
[TBL] [Abstract][Full Text] [Related]
2. Patient-advocate-led global coalition adapting fit-for-purpose outcomes measures to assure meaningful inclusion of DEEs in clinical trials.
Hecker J; Conecker G; Chapman C; Hommer R; Ludwig NN; Sevinc G; Te S; Wojnaroski M; Downs J; Berg AT
Ther Adv Rare Dis; 2024; 18():26330040241249762. PubMed ID: 38911512
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.
Sills GJ
Ther Adv Neurol Disord; 2023; 16():17562864231191000. PubMed ID: 37655228
[TBL] [Abstract][Full Text] [Related]
4. An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies.
Martin P; Reeder T; Sourbron J; de Witte PAM; Gammaitoni AR; Galer BS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445144
[TBL] [Abstract][Full Text] [Related]
5. Natural History Studies and Clinical Trial Readiness for Genetic Developmental and Epileptic Encephalopathies.
Palmer EE; Howell K; Scheffer IE
Neurotherapeutics; 2021 Jul; 18(3):1432-1444. PubMed ID: 34708325
[TBL] [Abstract][Full Text] [Related]
6. What are the considerations when initiating treatment for epilepsy in children?
Pisani F; Spagnoli C
Expert Rev Neurother; 2023; 23(12):1081-1096. PubMed ID: 38032395
[TBL] [Abstract][Full Text] [Related]
7. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum.
Guerrini R; Conti V; Mantegazza M; Balestrini S; Galanopoulou AS; Benfenati F
Physiol Rev; 2023 Jan; 103(1):433-513. PubMed ID: 35951482
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England.
Raspin C; Shankar R; Barion F; Pollit V; Murphy J; Sawyer L; Danielson V
J Med Econ; 2021; 24(1):1037-1051. PubMed ID: 34348576
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol: metabolism and clinical efficacy in epileptic patients.
Dell'Isola GB; Verrotti A; Sciaccaluga M; Dini G; Ferrara P; Parnetti L; Costa C
Expert Opin Drug Metab Toxicol; 2024 Mar; 20(3):119-131. PubMed ID: 38465404
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of Developmental and Epileptic Encephalopathy and of Intellectual Disability and Epilepsy in Children.
Poke G; Stanley J; Scheffer IE; Sadleir LG
Neurology; 2023 Mar; 100(13):e1363-e1375. PubMed ID: 36581463
[TBL] [Abstract][Full Text] [Related]
11. Beyond the Norm: A Report of a Rare Case of Sodium Channel 8 Alpha (SCN8A) Gene-Related Epilepsy Unveiled in a Nine-Year-Old Child.
K SSNSP; Vagha K; Varma A; Javvaji CK; Bhanushali K; Malik A; Handargule A
Cureus; 2024 May; 16(5):e59775. PubMed ID: 38846250
[TBL] [Abstract][Full Text] [Related]
12. Fenfluramine: a plethora of mechanisms?
Sourbron J; Lagae L
Front Pharmacol; 2023; 14():1192022. PubMed ID: 37251322
[TBL] [Abstract][Full Text] [Related]
13. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
[TBL] [Abstract][Full Text] [Related]
14. Respiratory Dysfunction in Epileptic Encephalopathies: Insights and Challenges.
Khan MA; Dev S; Kumari M; Mahak F; Umair A; Rasool M; Kumari A; Payal F; Panta U; Deepa F; Varrassi G; Khatri M; Kumar S
Cureus; 2023 Sep; 15(9):e46216. PubMed ID: 37905295
[TBL] [Abstract][Full Text] [Related]
15. Norwegian population-based study of effectiveness of vagus nerve stimulation in patients with developmental and epileptic encephalopathies.
Kostov KH; Kostov H; Larsson PG; Henning O; Aaberg KM; Egge A; Peltola J; Lossius MI
Epilepsia Open; 2024 Apr; 9(2):704-716. PubMed ID: 38318727
[TBL] [Abstract][Full Text] [Related]
16. Genetic and clinical variations of developmental epileptic encephalopathies.
Kaya Özçora GD; Söbü E; Gümüş U
Neurol Res; 2023 Mar; 45(3):226-233. PubMed ID: 36731496
[TBL] [Abstract][Full Text] [Related]
17. The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results.
Johannessen Landmark C; Potschka H; Auvin S; Wilmshurst JM; Johannessen SI; Kasteleijn-Nolst Trenité D; Wirrell EC
Epilepsia; 2021 Apr; 62(4):857-873. PubMed ID: 33638459
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
19. Variable Expression of GABAA Receptor Subunit Gamma 2 Mutation in a Nuclear Family Displaying Developmental and Encephalopathic Phenotype.
Nwosu G; Reddy SB; Riordan HRM; Kang JQ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077081
[TBL] [Abstract][Full Text] [Related]
20. Impact of developmental and epileptic encephalopathies on caregivers: A literature review.
Gallop K; Lloyd AJ; Olt J; Marshall J
Epilepsy Behav; 2021 Oct; 124():108324. PubMed ID: 34607217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
